Tildrakizumab

Introduction Overview

Generic Name

tildrakizumab

Brand Name

Ilumya

Dosage Form

subcutaneous injection (100 mg/mL)

Drug Class

Interleukin inhibitors

Pharmacokinetics

Absorption:
Tildrakizumab is administered via subcutaneous injection, allowing gradual absorption into the systemic circulation. After subcutaneous administration, peak plasma concentrations are typically achieved within 6 to 10 days. The bioavailability following subcutaneous administration is approximately 73%, which reflects good systemic exposure necessary for therapeutic effect. Absorption is influenced by local blood flow, injection site, and patient-specific factors such as body mass index. Clinical data indicate consistent pharmacokinetic profiles across patient populations, with minimal variability in absorption.

Distribution:
Tildrakizumab distributes primarily within the vascular and extracellular spaces due to its large molecular size as a monoclonal antibody (IgG1/kappa). Its volume of distribution is relatively low, estimated to be approximately 10-12 liters, consistent with monoclonal antibodies that typically do not extensively penetrate tissues. Distribution is restricted by size and Fc receptor interactions, leading to preservation within plasma and interstitial fluid compartments relevant to immunomodulation of inflamed psoriatic skin.

Metabolism:
As a monoclonal antibody, tildrakizumab undergoes proteolytic catabolism into small peptides and amino acids, primarily through the reticuloendothelial system and lysosomal degradation pathways in cells. It is not metabolized by cytochrome P450 enzymes, reducing potential for hepatic metabolism-associated drug interactions. The lack of hepatic metabolism means that hepatic impairment has minimal influence on the pharmacokinetics of tildrakizumab.

Elimination:
The elimination half-life of tildrakizumab is approximately 20 to 28 days, supporting the dosing interval of every 12 weeks during maintenance. Clearance occurs predominantly via non-specific catabolic degradation common to IgG antibodies. Renal elimination is negligible due to the large molecule size preventing filtration through the glomeruli. Clinical studies have shown that steady-state concentrations are achieved after the third dose, consistent with accumulation over repeated administration. The long half-life facilitates sustained therapeutic levels with infrequent dosing, improving patient adherence and maintaining immunomodulatory effects.

Dosage Forms

Available Dosage Forms:
Ilumya is available exclusively as a subcutaneous injection supplied in a prefilled syringe. Each prefilled syringe contains 100 mg of tildrakizumab in 1 mL of solution (100 mg/mL). The solution is a clear to slightly opalescent, colorless to slightly yellow liquid. The product does not come in other dosage forms such as oral or intravenous preparations.

Dosages for Adults and Adolescents:
Ilumya is FDA-approved for adults with moderate-to-severe plaque psoriasis. The recommended dosing regimen begins with an initial dose of 100 mg administered subcutaneously at weeks 0 and 4. Following induction, maintenance dosing consists of 100 mg subcutaneously every 12 weeks. Injection sites include the thighs, abdomen, or upper arms, and dosing should be overseen by a healthcare professional. Dosing adjustments are not generally needed for hepatic or renal impairment, and pediatric use has not been established.

Specific Patient Populations:
Ilumya is indicated for adult patients and is not approved for pediatric patients; thus, safety and efficacy have not been established in patients under 18 years of age. There are no specific dose adjustments for elderly patients or those with mild-to-moderate hepatic or renal impairment, but clinical monitoring is recommended. Patients with active infections should defer treatment until resolution, and tuberculosis screening must be conducted before initiation. Use during pregnancy and lactation requires careful risk-benefit assessment due to limited data. Illumya is administered exclusively by healthcare providers to assure proper technique and monitoring.

Mechanism Of Action

Ilumya (tildrakizumab) is a humanized immunoglobulin G1/kappa monoclonal antibody that specifically targets the interleukin-23 (IL-23) cytokine pathway, a key driver in the pathogenesis of moderate-to-severe plaque psoriasis. It selectively binds to the p19 subunit of IL-23, thereby inhibiting its interaction with the IL-23 receptor on immune cells. IL-23 is critical in promoting the differentiation, survival, and proliferation of T helper 17 (Th17) cells, which produce inflammatory cytokines implicated in psoriatic skin inflammation.

By blocking IL-23 binding, Ilumya interrupts the downstream release of pro-inflammatory cytokines such as interleukin-17 (IL-17), tumor necrosis factor-alpha (TNF-α), and other chemokines that contribute to keratinocyte hyperproliferation, epidermal thickening, and infiltration of inflammatory cells into the dermis and epidermis. This inhibition reduces the inflammatory cascade responsible for the plaques, scales, and erythema characteristic of psoriasis.

Compared to agents that block IL-12/23 p40 subunits (such as ustekinumab), Ilumya's p19 subunit specificity provides targeted suppression of IL-23 without affecting IL-12 pathways, potentially preserving host defense functions mediated by IL-12. This selective blockade may also reduce the risk of side effects associated with IL-12 inhibition.

Clinically, Ilumya’s mechanism translates into significant improvement in skin clearance and symptom reduction, with efficacy demonstrated in randomized trials showing a majority of patients achieving PASI 75 (75% improvement in psoriasis severity) within 12 weeks of therapy. The drug’s long half-life and sustained receptor occupancy allow for convenient dosing every 12 weeks after initial loading doses. Research indicates that Ilumya also reduces inflammatory cell infiltration and molecular markers within psoriatic lesions, supporting its targeted immunomodulatory effects.

Pharmacological Actions

Selective inhibition of the interleukin-23 (IL-23) pathway by binding to the p19 subunit.
Suppression of T helper 17 (Th17) cell expansion and subsequent reduction of IL-17 production.
Reduction of pro-inflammatory cytokine and chemokine release involved in psoriasis pathogenesis.
Modulation of immune system overactivity specifically related to autoimmune skin inflammation.
Inhibition of keratinocyte hyperproliferation and epidermal thickening through downstream effects.
Reduction of recruitment and activation of inflammatory cells in psoriatic skin lesions.
Preservation of IL-12 mediated immune responses due to selective IL-23 targeting.
Prolonged immunomodulatory effects facilitated by monoclonal antibody structure and long half-life.
Decreases tissue damage and plaque formation characteristic of moderate-to-severe plaque psoriasis.
Immunosuppressive action contributes to increased susceptibility to infections.
Minimal impact on cytochrome P450 enzymes and drug metabolism pathways.
Targets cytokine signaling pathways distinct from tumor necrosis factor (TNF) inhibitors.
Distinct mechanism compared to IL-17 inhibitors though overlapping inflammatory pathways are affected.

Therapeutic Or Clinical Uses

Treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.
Reduction of psoriatic plaques, scales, erythema, and associated skin itching and discomfort.
Management of chronic autoimmune-mediated skin inflammation to improve skin clearance.
Long-term maintenance therapy for plaque psoriasis with infrequent dosing intervals.
Use in patients unsuitable or intolerant to other systemic psoriasis therapies including biologics.
Improvement in quality of life and physical functioning by controlling psoriasis symptoms.
Potential off-label use studies are ongoing for psoriatic arthritis but not currently FDA approved.
Therapy for patients who failed or experienced adverse effects with prior biologic treatments.
Reduction of cytokine-mediated inflammation underlying disease progression in psoriasis.
Use as part of integrated psoriasis management including topical agents and phototherapy.
Alternative to TNF-alpha blockers and IL-17 inhibitors for targeted immunomodulation.
Applicable in patients with stable or unstable plaque psoriasis requiring systemic intervention.
Possibility to combine with other treatments under close clinical supervision.

Side Or Adverse Effects

Injection site reactions including pain, itching, redness, swelling, bruising, or bleeding.
Upper respiratory infections symptoms such as stuffy nose, sneezing, and sore throat.
Diarrhea reported as a common gastrointestinal side effect.
Increased risk of infections, including serious and potentially fatal infections.
Hypersensitivity reactions including hives, angioedema, difficulty breathing, and facial swelling.
Potential for reactivation of latent tuberculosis; pre-treatment screening recommended.
Rare serious allergic reactions necessitating immediate medical intervention.
Possible fever, chills, and sweating indicating infection development during therapy.
Muscle pain and skin sores may be indicative of systemic infection or adverse effect.
Respiratory symptoms including cough, shortness of breath, and hemoptysis (coughing pink or red mucus).
Weight loss and abdominal symptoms such as pain and diarrhea potentially related to infection.
Low incidence of immunogenicity but potential for anti-drug antibody formation.
No reported hepatotoxicity or significant laboratory abnormalities directly linked to Ilumya.
Limited data on long-term safety; ongoing monitoring for malignancies and immunosuppression effects.
Not recommended for use with live vaccines due to immunosuppressive effect.

Precautions

Screen patients for active or latent tuberculosis infection prior to initiation of therapy.
Avoid administration in patients with known hypersensitivity to tildrakizumab or any excipients.
Suspend treatment during serious infections until resolution and clinical stability.
Use cautiously in patients with chronic or recurrent infections given immunosuppressive action.
Do not administer live vaccines concurrently or within a certain period pre/post therapy.
Pregnancy and breastfeeding: Use only if clearly needed; assess risk versus benefit.
Monitor closely for allergic reactions during and following administration.
Patients should report any signs of infection, including fever, chills, or localized symptoms.
Inform patients of the importance of adherence to prescribed dosing intervals.
Educate patients regarding injection site care and symptoms warranting medical attention.
Adequately store and handle the injectable product to maintain stability and sterility.
Assess immunization status and update vaccines prior to initiating Ilumya therapy.
Avoid use in pediatric populations due to lack of established safety and efficacy.
Consider comorbidities that might increase risk of complications from immunosuppression.
Evaluate overall immune status and potential interaction with concurrent immunomodulators.

Warnings

Increased risk of serious infections including bacterial, fungal, and viral infections.
Potential reactivation of latent tuberculosis; confirm negative status before starting therapy.
Serious allergic reactions including anaphylaxis and angioedema can occur; emergency treatment is required.
Do not administer live vaccines during therapy due to risk of vaccine-related infection.
Monitor patients closely for signs of infections, including unusual skin sores or respiratory symptoms.
Ilumya may impair immune system function leading to increased susceptibility to opportunistic infections.
Discontinue therapy immediately if a severe allergic reaction occurs.
Patients should be instructed to promptly report symptoms such as fever, chills, cough, or urinary discomfort.
Careful screening and monitoring recommended in patients with a history of infections or immunodeficiency.
Use caution when administering in patients with chronic infections, including hepatitis B or C.
Safety and efficacy in pediatric patients not established; use is not recommended in this group.
Uncertainty about effects during pregnancy warrants careful use and consultation with healthcare providers.
Potential rare risk of malignancies with long-term immunosuppression; monitor accordingly.
Avoid storing medication outside recommended temperature ranges to maintain efficacy.
Notify healthcare provider if new infections develop or if there is a history of recurrent infections.

Contraindication

Known hypersensitivity to tildrakizumab or any component of the Ilumya formulation.
Active serious infections including tuberculosis, sepsis, or opportunistic infections.
Concurrent administration with live vaccines during treatment period.
Use in pediatric patients under 18 years due to lack of safety and efficacy data.
Patients with prior severe allergic reactions to monoclonal antibodies with similar structures.
Known hypersensitivity to excipients such as polysorbate 80 that may cause allergic reactions.
Severe immunodeficiency states where immunosuppression poses unacceptable risks.
Pregnant women unless the potential benefit outweighs potential fetal risks and prescribed cautiously.
Breastfeeding women unless decided on a case-by-case basis after medical consultation.
Concomitant use with other biologic immunosuppressants without medical supervision.
Use in patients with unresolved infections or suspected active tuberculosis.
Contrast hypersensitivity when combined with agents containing polysorbate derivatives.
History of malignancy unless controlled and benefit-risk assessment favors therapy.
Known severe dermatological allergy unrelated to psoriasis that may confound diagnosis.
Inability to comply with administration schedule or monitoring requirements.

Drug Interactions

No clinically significant drug interactions identified with cytochrome P450 substrates due to monoclonal antibody metabolism.
Concomitant use with other immunosuppressive therapies may increase risk of infections.
Live vaccines are contraindicated during and shortly after treatment with Ilumya due to immunosuppression.
Caution advised when used with immunomodulators or biologics that affect immune system.
No data indicating interaction with commonly used medications such as antihypertensives or statins.
Monitor for infection signs when combined with systemic corticosteroids or chemotherapy agents.
Potential additive immunosuppressive effects with concurrent biological agents such as TNF inhibitors.
Limited data on interactions with herbal products or supplements; precaution advised.
No known interaction with oral contraceptives or hormone replacement therapy.
No significant effect on pharmacokinetics of cytochrome P450 metabolized drugs expected.
Warfarin and other anticoagulants unlikely to have interaction but monitor for bleeding if infection occurs.
Vaccine efficacy may be diminished; avoid live vaccines or ensure vaccination before treatment.
Potential theoretical interaction with other monoclonal antibodies in development or trials.
Patients should report initiation of any new medication to healthcare providers during therapy.
No known food interactions based on current pharmacological profile.

Preparations Of The Drug

Available as a single-dose prefilled syringe containing 100 mg/mL tildrakizumab injection.
Each syringe contains 1 mL of clear to slightly opalescent, colorless to slightly yellow liquid solution.
Contains inactive ingredients including L-histidine, L-histidine hydrochloride monohydrate, polysorbate 80, sucrose, and water for injection.
Supplied in cartons with one prefilled syringe, requiring refrigeration between 2°C to 8°C (36°F to 46°F).
May be stored at room temperature (up to 25°C or 77°F) for a maximum of 30 days before use.
Do not freeze or shake the solution to preserve molecular integrity and efficacy.
Prefilled syringes include a safety mechanism to protect against needle injury after administration.
The product is distributed by Sun Pharmaceutical Industries, Inc., and manufactured in India with tildrakizumab-asmn sourced from South Korea.
Packaging includes instructions for proper removal, handling, and administration by a healthcare professional.
Carton labeling specifies lot number, expiration date, and storage conditions to ensure drug quality.
Tamper-evident packaging ensures product integrity during shipment and storage.
Needle cover should be removed immediately prior to injection to maintain sterility.
Discard unused or expired syringes according to local regulations for biological waste.
The drug is designated with J-code J3245 for billing related to the 1 mg injection in healthcare settings.
Patient support programs may accompany product distribution to assist with administration and financial aid.